Brainstorm Cell Therapeutics Inc. (tester2)
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Brainstorm Cell Therapeutics Inc. (“TEST_SN”) (NYSE: BCLI) and None (“None”) (None: None). Investors who purchased TEST_SN and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BCLI..
Investigation Details
The investigation concerns whether TEST_SN’s board of directors breached its fiduciary duties and failed to provide relevant information to its shareholders before the merger.
test
What’s Next?
If you are aware of any facts relating to this investigation or purchased TEST_SN shares, you can assist this investigation by visiting the firm’s site: bgandg.com/BCLI.. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller